Drug intelligence / Profile preview

YH0618 (Hong Kong Cancer Fund)

Development stage: Unknown
Lead developer: Hong Kong Cancer Fund
Administration: Oral

Overview

YH0618 is a botanical formulation, specifically described as a medicinal soup, investigated for its potential to mitigate chemotherapy-induced toxicities in cancer patients. It has been evaluated in clinical trials to assess its efficacy in reducing dermatologic toxicity, hematotoxicity, hepatotoxicity, and nephrotoxicity associated with standard chemotherapy regimens. As a supportive care intervention, YH0618 is intended to improve the tolerability of cancer treatments and enhance the quality of life for patients undergoing chemotherapy. The formulation is typically administered orally as a decoction.

Other names: YH0618 soupYH-0618 soupYH 0618 soup

Targets

KRT (Keratin, type I cuticular Ha7)SMAD3 (SMAD family member 3)

Beyond the preview

Go deeper on YH0618 (Hong Kong Cancer Fund).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH0618 (Hong Kong Cancer Fund).

Explore the full profile